Tanja Obradovic: Interesting update at ESMO 2024 on cancer-induced cachexia as PhII trial of ponsegromab

Tanja Obradovic posted on LinkedIn:

“Interesting update will come at ESMO 2024 on possible option for cancer-induced cachexia as PhII trial of ponsegromab, monoclonal antibody directed against the human growth differentiation factor 15 (GDF15; MIC-1) in non-small cell lung (NSCLC), pancreatic, colorectal cancer (CRC) patients is selected as late-breaking presentation.
(trial link).

Considering challenges of managing cachexia under cancer therapy positive update will bring truly important option for cancer patients.”

Source: Tanja Obradovic/LinkedIn

Tanja Obradovic is the Vice President of Oncology Scientific Affairs at ICON PLCh. She has over 20 years of clinical research experience and has led major pharmaceutical companies for 13 years. Her research focuses on small molecules, antibodies, cell and gene therapy, and major immunotherapy of PD1 inhibitors.